Background Warfarin remains a difficult drug to use due to the large variability in dose response. Clear understanding of the accuracy of warfarin pharmacogenetic dosing methods might lead to appropriate control of anticoagulation. Objective This study aims to evaluate the accuracy of warfarin dosing table and two pharmacogenetic algorithms, namely the algorithms of Gage et al. (Clin Pharmacol Ther 84:326–331, 2008), and the International Warfarin Pharmacogenetics Consortium algorithm (IWPC) in a real Egyptian clinical setting. Additionally, three non-pharmacogenetic dosing methods (the Gage, IWPC clinical algorithms and the empiric 5 mg/day dosing) were evaluated. Setting Sixty-three Egyptian patients on a stable therapeutic warfarin dose were included. Patients were recruited from the outpatient clinic of the critical care medicine department. Methods CYP2C9 and VKORC1 polymorphisms were genotyped by real time PCR system. Predicted doses by all dosing methods were calculated and compared with the actual therapeutic warfarin doses. Results The Gage algorithm (adjusted R2 = 0.421, and mean absolute error (MAE) = 3.3), and IWPC algorithm (adjusted R2 = 0.419, MAE = 3.2) produced better accuracy than did the warfarin dosing table (adjusted R2 = 0.246, MAE = 3.5), the two clinical algorithms (R2 = 0.24, MAE = 3.7) and the fixed dose approach (MAE = 3.9). However, all dosing models produced comparable clinical accuracy with respect to proportion of patients within 1 mg/day of actual dose (ideal dose). Non-pharmacogenetic methods severely over-predicted dose (defined as ≥2 mg/day more than actual dose) compared to the three pharmacogenetic models. In comparison to non-pharmacogenetic methods, the three pharmacogenetic models performed better regarding the low dose group in terms of percentage of patients within ideal dose. In the high dose group, none of the dosing models predicted warfarin doses within ideal dose. Conclusion Our study showed that genotype-based dosing improved prediction of warfarin therapeutic dose beyond that available with the fixed-dose approach or the clinical algorithms, especially in the low-dose group. However, the two pharmacogenetic algorithms were the most accurate.
This is a preview of subscription content, log in to check access.
We express our deep appreciation and thankfulness to the Critical Care Medicine Department, Cairo University Hospitals and all its members for all the help and support.The authors thank Walid Salah at Analysis, Cairo, Egypt for his laboratory assistance.
This study was completely self funded.
Conflicts of interest
None to declare.
Takeuchi F, Kashida M, Okazaki O, Tanaka Y, Fukuda S, Kashima T, et al. Evaluation of pharmacogenetic algorithm for warfarin dose requirements in Japanese patients. Circ J. 2010;74:977–82.PubMedCrossRefGoogle Scholar
Cavallari LH, Shin J, Minoli A, Perera MA. Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy. 2011;31(12):1192–207.PubMedCrossRefGoogle Scholar
Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis. 2008;25:45–51.PubMedCrossRefGoogle Scholar
Hillman MA, Wilke RA, Yale SH, Vidaillet HJ, Caldwell MD, Glurich I, et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res. 2005;3:137–45.PubMedCrossRefGoogle Scholar
Millican EA, Lenzini PA, Milligan PE, Grosso L, Eby C, Deych E, et al. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood. 2007;110:1511–5.PubMedCrossRefGoogle Scholar
Tham LS, Goh BC, Nafziger A, Guo JY, Wang LZ, Soong R, et al. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther. 2006;80:346–55.PubMedCrossRefGoogle Scholar
Gage BF, Eby C, Johnson JA, Deych E, Reider MJ, Ridker PM, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84:326–31.PubMedCrossRefGoogle Scholar
Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR. McLeod HL use pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost. 2004;91(1):87–94.PubMedGoogle Scholar
The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753–64.CrossRefGoogle Scholar
Roper N, Storer B, Bona R, Fang M. Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J Mol Diagn. 2010;12:283–91.PubMedCrossRefGoogle Scholar
Shin J, Cao D. Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort. Pharmacogenomics. 2011;12:125–34.PubMedCrossRefGoogle Scholar
Shaw PB, Donovan JL, Tran MT, Lemon SC, Burgwinkle P, Gore J. Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic. J Thromb Thrombolysis. 2010;30:220–5.PubMedCrossRefGoogle Scholar
Marin-Leblanc M, Perreault S, Bahroun I, Lapointe M, Mongrain I, Provost S, et al. Validation of warfarin pharmacogenetic algorithms in clinical practice. Pharmacogenomics. 2012;13(1):21–9.PubMedCrossRefGoogle Scholar
Wu AH, Wang P, Smith A, Haller C, Drake K, Linder M, et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics. 2008;9(2):169–78.PubMedCrossRefGoogle Scholar
Lubitz SA, Scott SA, Rothlauf EB, Agarwal A, Peter I, Doheny D, et al. Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J Thromb Haemost. 2010;8(5):1018–26.PubMedGoogle Scholar
Finkelman BS, Gage BF, Johnson JA, Brensinger CM, Kimmel SE. Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol. 2011;57(5):612–8.PubMedCrossRefGoogle Scholar
Sagrieya H, Berube C, Wen A, Ramakrishnan R, Mir A, Hamilton A, Altman RB. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet Genom. 2010;20:407–13.Google Scholar
Cavallari LH, Langaee TY, Momary KM, Shapiro NL, Nutescu EA, Coty WA, et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther. 2010;87:459–64.PubMedCrossRefGoogle Scholar
Shin J, Kayser SR. Accuracy of the pharmacogenetic dosing table in the warfarin label in predicting initial therapeutic warfarin doses in a large, racially diverse cohort. Pharmacotherapy. 2011;31:863–70.PubMedCrossRefGoogle Scholar
Schwartz JB, Kane L, Moore K. Wu AH Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin. J Am Med Dir Assoc. 2011;12(9):633–8.PubMedCrossRefGoogle Scholar
Garcia D, Regan S, Crowther M, Hughes R, Hylek E. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly populations. Chest. 2005;127:2049–56.PubMedCrossRefGoogle Scholar
Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1998;114:445S–69S.PubMedCrossRefGoogle Scholar
James A, Britt R, Raskino C, Thompson S. Factors affecting the maintenance dose of warfarin. J Clin Pathol. 1992;45:704–6.PubMedCrossRefGoogle Scholar
Booth S, Centurelli M. Vitamin k: a practical guide to the dietary management of patients on warfarin. Nutr Rev. 1999;57:288–96.PubMedCrossRefGoogle Scholar
Cropp J, Bussey H. A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy. 1997;17:917–28.PubMedGoogle Scholar
Absher R, Moore M, Parker M. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother. 2002;36:1512–7.PubMedCrossRefGoogle Scholar
Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009;5:e1000433.PubMedCrossRefGoogle Scholar
Carlquist J, Horne B, Mower C, Park J, Hutinghouse J, McKinney J, et al. An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction. J Thromb Thrombolysis. 2010;30:358–64.PubMedCrossRefGoogle Scholar
Lee M, Chen C, Chou C, Lu L, Chuang H, Chen Y, et al. Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics. 2009;10:1905–13.PubMedCrossRefGoogle Scholar
Shahin MHA, Khalifa SI, Gong Y, Hammad LN, Sallam MTH, El Shafey M, et al. Genetic and non genetic factors associated with warfarin dose requirements in Egyptian patient. Pharmacogenet Genom. 2011;21:130–5.CrossRefGoogle Scholar